Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Editas Medicine (EDIT) over the last 4 years, with Q3 2025 value amounting to $62000.0.

  • Editas Medicine's Amortizatization of Intangibles fell 9532.43% to $62000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 7479.0%. This contributed to the annual value of $5.8 million for FY2024, which is 2007.05% up from last year.
  • Per Editas Medicine's latest filing, its Amortizatization of Intangibles stood at $62000.0 for Q3 2025, which was down 9532.43% from $257000.0 recorded in Q2 2025.
  • Editas Medicine's 5-year Amortizatization of Intangibles high stood at $2.1 million for Q4 2023, and its period low was $62000.0 during Q3 2025.
  • For the 4-year period, Editas Medicine's Amortizatization of Intangibles averaged around $1.0 million, with its median value being $824500.0 (2023).
  • In the last 5 years, Editas Medicine's Amortizatization of Intangibles surged by 32228.92% in 2023 and then crashed by 9532.43% in 2025.
  • Quarter analysis of 4 years shows Editas Medicine's Amortizatization of Intangibles stood at $498000.0 in 2022, then soared by 322.29% to $2.1 million in 2023, then tumbled by 58.68% to $869000.0 in 2024, then plummeted by 92.87% to $62000.0 in 2025.
  • Its last three reported values are $62000.0 in Q3 2025, $257000.0 for Q2 2025, and $583000.0 during Q1 2025.